Scilex Holding Co…
USUSDScilex Holding Company (US:SCLX) — Biotechnology: Biological Products (No Diagnostic Substances). Anzahl der Börsen, an denen die Aktien des Unternehmens gehandelt werden: 1. Auf dieser Seite: Kurs und Chart, Dividenden, größte Aktionäre und Entwicklung der Aktienanzahl.
Über das Unternehmen
- Website
- scilexholding.com
- Sektor
- Health Care · Biotechnology: Biological Products (No Diagnostic Substances)
- Hauptsitz
- PALO ALTO, United States
- CEO
- Dr. Henry H. Ji Ph.D.
- Mitarbeiter
- 34
- Ausstehende Aktien
- 8.49 Mio. Stand 2026-08-10
- Streubesitz
- 5.69 Mio.
- Marktkapitalisierung
- 31.02 Mio. USD
- Insider
- 11.67%
- Institutionelle Anleger
- 8.52%
- Branche (SIC)
- Biological Products, (No Diagnostic Substances)
- Ausschüttungsquote
- Verlust
- FCF
- −17.8 Mio. USDFCF < 0
- Schulden
- 28.8 Mio. USD
- Dividendenserie
- —
- Gewinn, FCF und gezahlte Dividenden — für die 12 Monate bis 30.06.2026 (letzter Bericht des Unternehmens).
Beschreibung
Scilex Holding Company focuses on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. Its commercial products include ZTlido (lidocaine topical system) 1.8% (ZTlido), a prescription lidocaine topical product for the relief of neuropathic pain associated with postherpetic neuralgia (PHN), which is a form of post-shingles nerve pain; ELYXYB, a ready-to-use oral solution for the acute treatment of migraine with or without aura in adults; and GLOPERBA, a liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults. The company also develops three product candidates, including SP-102 (10 mg, dexamethasone sodium phosphate viscous gel - SEMDEXA), a novel viscous gel formulation of a used corticosteroid for epidural injections, which has completed a phase 3 study to treat lumbosacral radicular pain or sciatica; SP-103 (lidocaine topical system) 5.4%, a formulation of ZTlido for the treatment of chronic neck pain and low back pain (LBP) that has completed a phase 2 trial; and SP-104 (4.5 mg low-dose naltrexone hydrochloride delayed-release capsules), a novel low-dose delayed-release naltrexone hydrochloride, which has completed phase 1 trials for the treatment of fibromyalgia. It has an agreement with Oishi and Itochu to develop lidocaine tape products, including ZTlido and SP-103; Lifecore Biomedical, LLC for clinical trial material manufacturing and development services for SEMDEXA; and Tulex Master, which develops, tests, and manufactures clinical supplies of SP-104. Scilex Holding Company is based in Palo Alto, California.
Börsen und Ticker
| Börse | Ticker | Währung | Preis | Typ |
|---|---|---|---|---|
| US USA Stocks | SCLX | USD | 2.96 -15.19% | Stammaktie |
Dividenden
Keine Dividendenzahlungen gefunden (geprüft 10.10.2026). Das Unternehmen schüttet wahrscheinlich keine Dividenden aus.
Neuigkeiten diese Woche
Noch keine Nachrichten von der Website des Unternehmens.
Größte Anteilseigner
| Inhaber | Anteil | Aktien | Berichtsdatum |
|---|---|---|---|
| JI HENRY H (Officer and… | ≈8.02% | 680 884 | 2024-10-31 |
| Vanguard Capital Managem… | 3.55% | 301 292 | 2026-06-30 |
| SHAH JAISIM (Chief Execu… | ≈3.48% | 295 215 | 2024-12-18 |
| VANGUARD INDEX FUNDS-Van… | 2.56% | 217 510 | 2026-06-30 |
| CHUN JAY (Director) | ≈1.33% | 112 511 | 2024-10-18 |
| Blackrock Inc. | 1.29% | 109 417 | 2026-06-30 |
| VANGUARD INDEX FUNDS-Van… | 0.9% | 76 230 | 2026-06-30 |
| Vanguard Fiduciary Trust… | 0.54% | 45 822 | 2026-06-30 |
| Jacobs Levy Equity Manag… | 0.48% | 41 163 | 2026-06-30 |
| State Street Corporation | 0.42% | 35 376 | 2026-06-30 |
| UBS Group AG | 0.39% | 33 376 | 2026-06-30 |
| Renaissance Technologies… | 0.39% | 33 064 | 2026-06-30 |
| Citadel Advisors Llc | 0.32% | 27 497 | 2026-06-30 |
| WU YUE ALEXANDER (Direct… | ≈0.29% | 25 000 | 2024-10-17 |
| iShares Trust-iShares Mi… | 0.28% | 23 935 | 2026-08-31 |
| MA STEPHEN HOI (Chief Fi… | ≈0.27% | 22 840 | 2024-10-16 |
| Price (T.Rowe) Associate… | 0.25% | 20 920 | 2026-06-30 |
| Ashton Thomas Private We… | 0.22% | 18 482 | 2026-06-30 |
| -Price (T.Rowe) U.S. Equ… | 0.17% | 14 020 | 2026-06-30 |
| T. ROWE PRICE INDEX TRT,… | 0.08% | 6 900 | 2026-06-30 |
| VANGUARD Inst. INDEX Fd.… | 0.04% | 3 805 | 2026-06-30 |
| VANGUARD VALLEY FORGE FU… | 0.04% | 3 747 | 2026-06-30 |
| FOLLOWWILL DORMAN (Direc… | ≈0.03% | 2 300 | 2024-10-18 |
| LEMUS DAVID (Director) | ≈0.02% | 2 000 | 2024-10-17 |
| EQ Advisors Trust-1290 V… | 0.02% | 1 683 | 2026-06-30 |
| Brighthouse Funds Trust… | 0.01% | 627 | 2026-06-30 |
| STATE STREET Inst. INVES… | 0% | 120 | 2026-06-30 |
| SCILEX HOLDING CO (Benef… | — | 244.45 Mio. | 2025-12-30 |
